ASHLYN MONAGHAN: Open Payments
NPI 1265917256 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$994 in 58 payments from 14 companies in 2025. Trend: 2023 $658 · 2024 $412 · 2025 $994
Food & beverage: $994
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $247 |
| Lilly USA, LLC | 12 | $201 |
| PFIZER INC. | 5 | $82 |
| Amgen Inc. | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| ABBVIE INC. | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| GlaxoSmithKline, LLC. | 2 | $30 |
Products named: MOUNJARO, Ozempic, Wegovy, Auvelity, OTEZLA, JARDIANCE, NURTEC ODT, XIFAXAN.
Industry payments across TX — which companies pay providers there.
